EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Roxadustat for Erythropoiesis-Stimulating Agent Hyporesponsive Anemia in Hemodialysis: Multicenter Retrospective Analysis

Ilyas Ozturk iD, Meliha Ozkutlu, Merve Aktar, Cihan Heybeli iD, Can Huzmeli, Orhan Ozdemir, Seda Safak Ozturk, Tulin Akagun iD, Ekrem Kara iD, Neriman Sila Koc iD, Mehmet Tuncay, Tuncay Sahutoglu iD

Medicina · 28.02.2026 · 62 (3) · 460

DOI: 10.3390/medicina62030460 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Medicina, online erschienen am 28.02.2026. Verfasst von Ilyas Ozturk und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Kahramanmaras Necip Fazil City Hospital, 46050 Kahramanmaras, Türkiye. Hauptthemen laut MEDLINE: Anemia, Glycine, Hematinics, Isoquinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Anemia management in maintenance hemodialysis patients with erythropoiesis-stimulating agent (ESA) hyporesponsiveness remains challenging. Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, offers a mechanistically distinct alternative. Materials and Methods: This multicenter retrospective study analyzed 110 hemodialysis patients with persistent anemia (Hemoglobin (Hb) < 10 g/dL) despite ≥ 3 months of maximum-reimbursable-dose ESA therapy in Türkiye. Outcomes were evaluated between patients who switched to Roxadustat (n = 80) and those who continued ESA therapy (n = 30) over 6 months in a non-randomized, observational comparison.

Results

At baseline, median Hb levels were significantly lower in the Roxadustat-group than in the ESA-group (8.70 vs. 9.50 g/dL; p < 0.001), while weight-adjusted ESA doses were comparable (p = 0.332). By Month 6, the Roxadustat group achieved a significant Hb increase (from 8.70 to 9.95 g/dL), whereas the ESA-group showed no significant change (9.50 to 9.65 g/dL), and end-of-treatment Hb did not differ significantly between groups. The unadjusted mean Hb rise was greater in the Roxadustat cohort than in the ESA cohort (+1.40 ± 1.55 vs. +0.65 ± 1.93 g/dL; p = 0.037). However, after adjustment for baseline Hb (ANCOVA), baseline Hb predicted final Hb, while treatment group was not independently associated with final Hb. Transfusion requirements declined over follow-up in both groups. No new short-term safety signal was identified based on available clinical documentation.

Conclusions

Roxadustat improved Hb in ESA-hyporesponsive patients with lower baseline Hb, but adjusted analyses indicated that baseline severity influenced response. Targets were not consistently achieved; these findings are hypothesis-generating regarding dose optimization, treatment duration, and earlier initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnemiaGlycineHematinicsIsoquinolinesRenal DialysisAgedFemaleHumansMaleMiddle AgedHemoglobinsRetrospective StudiesTurkey

Stichwörter der Autor:innen

Anemiaerythropoietinhypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI)

Substanzen

GlycineHematinicsHemoglobinsIsoquinolinesroxadustat

Autor:innen und Institutionen

  • Department of Nephrology, Kahramanmaras Necip Fazil City Hospital, 46050 Kahramanmaras, Türkiye.
  • Department of Internal Medicine, University of Health Sciences, Mehmet Akif Inan Education and Research Hospital, 63040 Sanliurfa, Türkiye.
  • Department of Nephrology, Istanbul Aydin University, Medical Park Florya Hospital, 34295 Istanbul, Türkiye.
  • Department of Nephrology, Mus State Hospital, 49100 Mus, Türkiye.
  • Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 Izmir, Türkiye.
  • Department of Nephrology, Hatay Education and Research Hospital, 31027 Hatay, Türkiye.

ORCID-Profile: Ilyas Ozturk, Cihan Heybeli, Tulin Akagun, Ekrem Kara, Neriman Sila Koc, Tuncay Sahutoglu

Zitieren

APA

Ozturk, I., Ozkutlu, M., Aktar, M., Heybeli, C., Huzmeli, C., Ozdemir, O., Ozturk, S. S., Akagun, T., Kara, E., Koc, N. S., Tuncay, M., & Sahutoglu, T. (2026). Roxadustat for Erythropoiesis-Stimulating Agent Hyporesponsive Anemia in Hemodialysis: Multicenter Retrospective Analysis. Medicina, 62(3), 460. https://doi.org/10.3390/medicina62030460

Vancouver

Ozturk I, Ozkutlu M, Aktar M, Heybeli C, Huzmeli C, Ozdemir O, et al. Roxadustat for Erythropoiesis-Stimulating Agent Hyporesponsive Anemia in Hemodialysis: Multicenter Retrospective Analysis. Medicina. 2026;62(3):460. doi:10.3390/medicina62030460

BibTeX
@article{Ozturk2026,
  author = {Ozturk, Ilyas and Ozkutlu, Meliha and Aktar, Merve and Heybeli, Cihan and Huzmeli, Can and Ozdemir, Orhan and Ozturk, Seda Safak and Akagun, Tulin and Kara, Ekrem and Koc, Neriman Sila and Tuncay, Mehmet and Sahutoglu, Tuncay},
  title = {Roxadustat for Erythropoiesis-Stimulating Agent Hyporesponsive Anemia in Hemodialysis: Multicenter Retrospective Analysis},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {3},
  pages = {460},
  doi = {10.3390/medicina62030460}
}
Kostenlos starten →